Eli Lilly and Sosei enter into diabetes and metabolic disease deal, going after GPCR
Japan’s Sosei Heptares is partnering up with another big-name player: Eli Lilly.
Under the agreement, Eli Lilly will pay Sosei $37 million upfront with a possibility of up to $694 million for development and commercial milestones and then tiered royalties on global sales. The pair will aim to design small molecule drugs going after G protein-coupled receptor (GPCR) targets to treat diabetes and other metabolic diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.